✦ LIBER ✦

Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin

✍ Scribed by K. H. TANG; E. HERRMANN; I. PACHIADAKIS; E. PAULON; N. TATMAN; S. ZEUZEM; N. V. NAOUMOV

Book ID: 108605259
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 181 KB
Volume: 27
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2008.03628.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of chronic hepatitis C virus g

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha

✍ Mitchell L. Shiffman; Jennifer Salvatore; Sarah Hubbard; Angie Price; Richard K. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB 👁 1 views

Clinical trial: extended treatment durat

Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders

✍ M. NAGAKI; M. SHIMIZU; J. I. SUGIHARA; E. TOMITA; C. SANO; T. NAIKI; K. KIMURA; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB

Early virologic response after peginterf

Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C

✍ A. M. Di Bisceglie; R. H. Ghalib; F. M. Hamzeh; V. K. Rustgi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 547 KB

Individualized treatment duration for he

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

✍ Alessandra Mangia; Nicola Minerva; Donato Bacca; Raffaele Cozzolongo; Giovanni L 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB 👁 2 views

It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48-week treatment. Patients (n = 696) received peginterferon alfa-2a, 180 mg/week, or peginterferon alfa-2b, 1.5 mg/kg/week, p

Clinical usefulness of total hepatitis C

Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin

✍ V. González; E. Padilla; M. Diago; M. D. Giménez; R. Solà; L. Matas; S. Montoliu 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Randomised clinical trial: the efficacy

Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3

✍ S. S. Lee; M. Sherman; A. Ramji; S. Greenbloom; M. Elkashab; H. Pluta; N. Hilzen 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 312 KB